Key Points
- Rallybio major shareholder Adar1 Capital Management bought 50,000 shares on May 11 at an average price of $14.00, spending about $700,000 and increasing its stake by 6.41%.
- Adar1 also made several recent purchases, including 120,804 shares on May 4 and 35,101 shares on May 5, signaling continued insider buying activity in RLYB.
- Rallybio shares were trading near a 52-week high, but the company recently reported a quarterly loss of $1.46 per share, missing analyst expectations, and the stock currently carries an average Sell rating.
Rallybio Corporation (NASDAQ:RLYB - Get Free Report) major shareholder Adar1 Capital Management, Llc purchased 50,000 shares of the company's stock in a transaction dated Monday, May 11th. The stock was purchased at an average price of $14.00 per share, with a total value of $700,000.00. Following the completion of the purchase, the insider directly owned 829,784 shares in the company, valued at $11,616,976. The trade was a 6.41% increase in their position. The purchase was disclosed in a legal filing with the SEC, which is accessible through the SEC website. Large shareholders that own 10% or more of a company's stock are required to disclose their sales and purchases with the SEC.
Adar1 Capital Management, Llc also recently made the following trade(s):
- On Tuesday, May 12th, Adar1 Capital Management, Llc purchased 800 shares of Rallybio stock. The stock was purchased at an average price of $13.83 per share, with a total value of $11,064.00.
- On Tuesday, May 5th, Adar1 Capital Management, Llc purchased 35,101 shares of Rallybio stock. The stock was purchased at an average price of $14.00 per share, with a total value of $491,414.00.
- On Monday, May 4th, Adar1 Capital Management, Llc purchased 120,804 shares of Rallybio stock. The stock was purchased at an average price of $13.97 per share, with a total value of $1,687,631.88.
Rallybio Stock Performance
Shares of RLYB opened at $14.35 on Thursday. Rallybio Corporation has a 52 week low of $2.16 and a 52 week high of $15.31. The stock has a market capitalization of $75.91 million, a price-to-earnings ratio of -5.61 and a beta of -1.10. The stock has a fifty day moving average of $9.70 and a 200-day moving average of $6.93.
Rallybio (NASDAQ:RLYB - Get Free Report) last announced its quarterly earnings results on Wednesday, May 13th. The company reported ($1.46) EPS for the quarter, missing analysts' consensus estimates of ($1.20) by ($0.26). Rallybio had a negative net margin of 1,046.39% and a negative return on equity of 56.93%. The firm had revenue of $0.21 million during the quarter, compared to the consensus estimate of $0.23 million.
Institutional Inflows and Outflows
Several hedge funds have recently made changes to their positions in the business. Renaissance Technologies LLC raised its position in shares of Rallybio by 16.9% in the 4th quarter. Renaissance Technologies LLC now owns 835,692 shares of the company's stock worth $573,000 after acquiring an additional 120,892 shares in the last quarter. Citadel Advisors LLC raised its position in shares of Rallybio by 576.1% in the 3rd quarter. Citadel Advisors LLC now owns 438,705 shares of the company's stock worth $219,000 after acquiring an additional 373,821 shares in the last quarter. Geode Capital Management LLC raised its position in shares of Rallybio by 1.2% in the 4th quarter. Geode Capital Management LLC now owns 248,005 shares of the company's stock worth $170,000 after acquiring an additional 2,996 shares in the last quarter. Susquehanna International Group LLP raised its position in shares of Rallybio by 485.9% in the 3rd quarter. Susquehanna International Group LLP now owns 136,294 shares of the company's stock worth $68,000 after acquiring an additional 113,031 shares in the last quarter. Finally, XTX Topco Ltd raised its position in shares of Rallybio by 64.6% in the 4th quarter. XTX Topco Ltd now owns 97,313 shares of the company's stock worth $67,000 after acquiring an additional 38,205 shares in the last quarter. 90.34% of the stock is owned by institutional investors.
Wall Street Analyst Weigh In
Several brokerages recently issued reports on RLYB. Weiss Ratings reaffirmed a "sell (d-)" rating on shares of Rallybio in a research report on Friday, May 8th. Wall Street Zen raised Rallybio to a "hold" rating in a research report on Saturday, March 28th. One analyst has rated the stock with a Sell rating, According to data from MarketBeat.com, the stock presently has an average rating of "Sell".
Get Our Latest Analysis on Rallybio
About Rallybio
(
Get Free Report)
Rallybio Therapeutics, Inc (NASDAQ: RLYB) is a clinical‐stage biotechnology company focused on developing and commercializing therapies for people living with rare genetic diseases. The company's scientific approach leverages diverse modalities—including monoclonal antibodies, small molecules and enzyme replacement—to address high‐unmet‐need conditions in areas such as immunodeficiency, metabolic disorders and dermatologic diseases. Rallybio's pipeline is designed to advance through registrational clinical trials with the goal of delivering first‐in‐class or best‐in‐class therapies to patients who currently have limited or no approved treatment options.
Among Rallybio's lead programs is RBX‐100, an investigational therapy for congenital athymia, a rare pediatric immunodeficiency.
Featured Stories
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. Please send any questions or comments about this story to [email protected].
